Journal
SCIENCE
Volume 297, Issue 5578, Pages 102-104Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.1071489
Keywords
-
Categories
Funding
- NCI NIH HHS [R01-CA85610, K08-CA75967-01, R01-CA89305-01] Funding Source: Medline
Ask authors/readers for more resources
Pharmacological inactivation of oncogenes is being investigated as a possible therapeutic strategy for cancer. One potential drawback is that cessation of such therapy may allow reactivation of the oncogene and tumor regrowth. We used a conditional transgenic mouse model for MYC-induced tumorigenesis to demonstrate that brief inactivation of MYC results in the sustained regression of tumors and the differentiation of osteogenic sarcoma cells into mature osteocytes. Subsequent reactivation of MYC did not restore the cells malignant properties but instead induced apoptosis. Thus, brief MYC inactivation appears to cause epigenetic changes in tumor cells that render them insensitive to MYC-induced tumorigenesis. These results raise the possibility that transient inactivation of MYC may be an effective therapy for certain cancers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available